Get started
Author

Joseph Michael Guenther

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
2011 · Matthew J. Ellis, Vera J. Suman, et al. · Journal of Clinical Oncology · 551
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
2024 · E. Shelley Hwang, Terry Hyslop, et al. · JAMA · 88
PDF
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor–Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)
2020 · E. Shelley Hwang, Terry Hyslop, et al. · Journal of Clinical Oncology · 29
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
2024 · Cynthia X. Ma, Vera J. Suman, et al. · JAMA Oncology · 27
PDF
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ
2024 · Ann H. Partridge, Terry Hyslop, et al. · JAMA Oncology · 17
PDF
Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ
2023 · Seema A. Khan, Xinlei Mi, et al. · JAMA Surgery · 9
PDF
Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
2021 · Cynthia X Ma, Vera Suman, et al. · Cancer Research · 9
Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)
2021 · Matthew J Ellis, Vera Suman, et al. · Cancer Research · 3
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
2024 · Weiss, Anna, Dockter, Travis J., et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill) · 1
PDF
Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)
2022 · Cynthia X Ma, Meenakshi Anurag, et al. · Cancer Research · 1
Combination Risk-Reducing Breast, Gynecologic and Reconstructive Surgery Among High-Risk Women: Does Surgical Order Impact Outcome?
2015 · Rachel G. Sinkey, James C. Pavelka, et al. · Journal of Gynecologic Surgery · 1
Reassessment of Published Comparative Performance Model for 31-GEP and CP-GEP in Sentinel Lymph Node Biopsy Prediction in Cutaneous Melanoma
2026 · Peter A. Prieto, Eric Whitman, et al. · SKIN The Journal of Cutaneous Medicine
PDF
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial
2024 · Ma, Cynthia X., Suman, Vera J., et al. · University of Chicago
Abstract PD15-12: PD15-12 A pre-surgical window trial of oral tamoxifen versus transdermal 4-hydroxytamoxifen gel in women with estrogen receptor positive duct carcinoma in situ (DCIS)
2023 · Oukseub Lee, Xinlei Mi, et al. · Cancer Research
Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial
2022 · Matthew J. Ellis, Meenakshi Anurag, et al. · Cancer Research
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
2020 · Babiera, Gildy V., Esserman, Laura J., et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)
PDF
Metaplastic Carcinoma of the Breast
2002 · Alfonso Camberos, George Barnes, et al. · The Cancer Journal
Do Primary Tumor Stage and Lymphatic Tumor Burden Affect the False Negative Rate of Sentinel Lymph Nodes in Colorectal Cancer?
2002 · G. A. Broderick-Villa, A. S. Ko, et al. · The Cancer Journal
Works count: 18
Citation count: 736
H-index: 7
I10-index: 5
Year
Topic
Type